CARE Guidance: Treatment Considerations for mCRPC

Metastatic CRPC (mCRPC) has been a focus for the CARE Genitourinary Faculty since 2014, when they met at the American Society of Clinical Oncology (ASCO) annual meeting to discuss current challenges and considerations in the management of mCRPC. It was decided that multiple specialties (radiation oncology, urology, and medical oncology) needed to be involved in this discussion in order to provide their expertise and offer a variety of perspectives to the group. During the meeting at ASCO 2014, a CARE Treatment Guidance for mCRPC was developed. 

Since then, more data and agents have become available. Members of the CARE Faculty met at the Canadian Urological Association (CUA) – Canadian Urologic Oncology Group (CUOG) Multidisciplinary Meeting 2015 (June 27, 2015) to further discuss treatment options and considerations in this disease category, with the ultimate goal of updating and augmenting the previous CARE guidance document.

This document contains the updated CARE Treatment Guidance and provides additional details on the treatment options, including updated trial information on how the agent should be used, supporting recommendations from ASCO and Cancer Care Ontario (CCO), and supportive care issues. 

The development of this publication was led by CARE GU Faculty members Drs. Sebastien Hotte, Brita Danielson and Alan So, and includes insights/perspectives from other leading key opinion leaders from across Canada (please see guidance references for full details on specialists involved).

Below is a link to the full report: